IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

IBI-10090 is a novel anti-inflammatory drug product, based on IBI's proprietary Verisome(TM) drug delivery platform technology, administered as a single injection into the anterior chamber of the eye that is designed to last approximately two to three weeks. IBI-10090 reduces the inflammation normally associated with cataract surgery and speeds the recovery of patients without the need for multiple daily topical eye drops. The pivotal trial involves multiple clinical sites throughout the United States and will enroll over 200 patients.

"We are very pleased to have reached this important milestone. IBI-10090 is our first product to reach the Phase 2/3 pivotal stage of clinical development," said William S. White, Chief Executive Officer of Icon Bioscience, Inc. "We believe IBI-10090 will offer patients and physicians a clinically superior alternative to the use of topical anti-inflammatory eye drops."